Comparison of Apixaban Versus Enoxaparin

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Feb 2, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated informed consent form
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• • 3. Able to communicate in English over the phone
• • 4. Male or female, age \>18 years
• • 5. Diagnosed with biopsy-proven, urothelial cell carcinoma (any T stage, N0-1, M0) with plan for radical cystectomy with urinary diversion and concurrent pelvic lymph node dissection as treatment
• Exclusion Criteria:
• • 1. Preoperative use of a therapeutic dose of anticoagulant (this notably does not exclude patients taking antiplatelet agents)
• • 2. Failure to undergo radical cystectomy with concurrent urinary diversion and pelvic lymph node dissection
• • 3. Failure to be discharged by post-operative day 14
• • 4. Failure to receive a script for enoxaparin or apixaban.
• • 5. Any medical condition which precludes treatment with either enoxaparin or apixaban (including dialysis, hemophilia or any other bleeding diathesis)